Myeloproliferative Neoplasms Clinical Trial
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected TKI for the treatment of newly diagnosed, previously untreated patients with Ph+ leukemia-cml/" >CML-CP. The Investigator selected TKI will be one of the following treatment options for first-line treatment of CML-CP - imatinib 400 mg QD or nilotinib 300 mg BID or dasatinib 100 mg QD or bosutinib 400 mg QD.
This study is a phase III, multi-center, open-label, randomized study of oral asciminib 80 mg QD versus Investigator selected TKI (imatinib, nilotinib, dasatinib, or bosutinib) in adult patients with newly diagnosed Ph+ CML-CP. All comparator TKIs will be made available, unless not permitted by local regulations or local Health Authority, or not approved for the treatment of CML in the country.
The study is designed to compare the efficacy of asciminib 80 mg QD with Investigator selected TKI for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP. The Investigator selected TKI will be one of the treatment options approved by major Health Authorities for first-line treatment of CML-CP - imatinib 400 mg QD or nilotinib 300 mg BID or dasatinib 100 mg QD or bosutinib 400 mg QD.
Approximately 402 patients will be randomized in a 1:1 ratio to asciminib and Investigator selected TKI.
Randomization will be stratified based on the following two stratification factors:
ELTS score (low versus intermediate versus high)
Pre-randomization selected TKI (imatinib versus 2G TKI (nilotinib or dasatinib or bosutinib)).
Prior to randomization, the Investigator, in consultation with the patient, considering the current treatment paradigm and patient characteristics and comorbidities, will make a selection of preference for imatinib or 2G TKI (nilotinib or dasatinib or bosutinib) if the patient is randomized to the comparator arm.
To further ensure that the distribution of patients, between imatinib and 2G TKIs (nilotinib or dasatinib or bosutinib), in the Investigator selected TKI arm is reflective of the use of these agents in clinical practice, the enrollment into the strata of imatinib versus 2G TKI (nilotinib or dasatinib or bosutinib) based on the pre-randomization selection of TKI will be managed by Interactive Response Technology to be approximately 50% versus 50%.
Treatment arms: The study will have 2 treatment arms:
Arm 1: asciminib 80 mg QD under fasting conditions
Arm 2: Investigator selected TKI that will include one of the below treatments:
Imatinib 400 mg QD administered with food
Nilotinib 300 mg BID administered under fasting conditions
Dasatinib 100 mg QD administered with or without meal
Bosutinib 400 mg QD administered with food.
No crossover of study treatment across arms and no change of study treatment within the Investigator selected TKI will be allowed.
Duration of Study treatment: Patients on the study will continue to receive the assigned treatment until the End of Study, or until premature discontinuation due to treatment failure, disease progression or intolerance or due to Investigator or participant decision.
Duration of study: The End of Study will occur 5 years from the last patient first treatment in the study. Patients who discontinue study treatment prematurely due to any reason, will be followed up for survival and progression (to AP/BC) until the End of Study.
Participants eligible for inclusion in this study must meet all of the following criteria:
Male or female patients ≥ 18 years of age.
Participants with CML-CP within 3 months of diagnosis.
Diagnosis of CML-CP (ELN 2020 criteria) with cytogenetic confirmation of Philadelphia chromosome
Documented chronic phase CML will meet all the below criteria (Hochhaus et al 2020):
< 15% blasts in peripheral blood and bone marrow,
< 30% blasts plus promyelocytes in peripheral blood and bone marrow,
< 20% basophils in the peripheral blood,
Platelet count ≥ 100 x 109/L (≥ 100,000/mm3),
No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0,or 1. 5. Adequate end organ function as defined by:
Total bilirubin < 3 x ULN; patients with Gilbert's syndrome may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN
Creatinine clearance (CrCl) ≥ 30 mL/min as calculated using Cockcroft-Gault formula,
Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN - ≤ 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis 6. Participants must have the following laboratory values within normal limits or corrected to within normal limits with supplements prior to randomization:
Potassium (potassium increase of up to 6.0 mmol/L is acceptable if associated with CrCl* ≥ 90 mL/min)
Total calcium (corrected for serum albumin); (calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is acceptable if associated with CrCl* ≥ 90 mL/min)
Magnesium (magnesium increase of up to 3.0 mg/dL or 1.23 mmol/L if associated with CrCl* ≥ 90 mL/min)
For patients with mild to moderate renal impairment (CrCl* ≥ 30 mL/min and <90 mL/min) - potassium, total calcium (corrected for serum albumin) and magnesium should be ≥ LLN or corrected to within normal limits with supplements prior to randomization.
*CrCl as calculated using Cockcroft-Gault formula 7. Ability to provide written informed consent prior to any study related screening procedures being performed.
8. Evidence of typical BCR-ABL1 transcript [e14a2 and/or e13a2] at the time of screening which is amenable to standardized Real time quantitative polymerase chain reaction (RQ-PCR) quantification.
Previous treatment of CML with any other anticancer agents including chemotherapy and/or biologic agents or prior stem cell transplant, with the exception of hydroxyurea and/or anagrelide. Treatment with either imatinib, or nilotinib, or dasatinib or bosutinib for ≤2 weeks is allowed, but no other treatment with other tyrosine kinase inhibitors prior to randomization is permitted.
Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required).
Impaired cardiac function or cardiac repolarization abnormality including but not limited to any one of the following:
History within 6 months prior to starting study treatment of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG)
Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block)
QTc ≥ 450 ms (male patients), ≥460 ms (female patients) on the average of three serial baseline ECG (using the QTcF formula) as determined by central reading. If QTcF ≥ 450 ms and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc.
Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
Concomitant medication(s) with a "Known risk of Torsades de Pointes" per www.crediblemeds.org/ that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.•Inability to determine the QTcF interval
Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection; uncontrolled arterial or pulmonary hypertension, uncontrolled clinically significant hyperlipidemia). Please refer to Section 6.3.1
History of significant congenital or acquired bleeding disorder unrelated to cancer.
Major surgery within 4 weeks prior to study entry or who have not recovered from prior surgery.
History of other active malignancy within 3 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively
History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis.
History of chronic liver disease leading to severe hepatic impairment, or ongoing acute liver disease.
Other protocol-defined Inclusion/exclusion criteria will apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 143 Locations for this study
Duarte California, 91010, United States
Los Angeles California, 90095, United States
Longmont Colorado, 80501, United States
Fort Myers Florida, 33901, United States
Fort Myers Florida, 33901, United States
Tallahassee Florida, 32308, United States
West Palm Beach Florida, 33401, United States
Chicago Illinois, 60637, United States
Peoria Illinois, 61615, United States
Iowa City Iowa, 52242, United States
Lexington Kentucky, 40536, United States
Worcester Massachusetts, 01655, United States
Ann Arbor Michigan, 48109, United States
Winston-Salem North Carolina, 27157, United States
Cincinnati Ohio, 45242, United States
Eugene Oregon, 97401, United States
Portland Oregon, 97239, United States
Sioux Falls South Dakota, 57105, United States
Chattanooga Tennessee, 37404, United States
Dallas Texas, 75246, United States
Dallas Texas, 75246, United States
Dallas Texas, 75246, United States
Dallas Texas, 75251, United States
Houston Texas, 77030, United States
Kingwood Texas, 77339, United States
Tyler Texas, 75702, United States
Gainesville Virginia, 20155, United States
Norfolk Virginia, 23502, United States
Kingswood New South Wales, 2747, Australia
Port Macquarie New South Wales, 2444, Australia
Woolloongabba Queensland, 4102, Australia
Adelaide South Australia, 5000, Australia
SouthPort , 4215, Australia
Linz Upper Austria, 4010, Austria
Wien , 1090, Austria
Bruxelles , 1000, Belgium
Hasselt , 3500, Belgium
Leuven , 3000, Belgium
Sofia , 1797, Bulgaria
Varna , 9010, Bulgaria
Calgary Alberta, T2N 4, Canada
Hamilton Ontario, L8V 1, Canada
Ottawa Ontario, K1H 8, Canada
Toronto Ontario, M5G 2, Canada
Hefei Anhui, 23000, China
Chongqing Chongqing, 40001, China
Guangzhou Guangdong, 51051, China
Shenzhen Guangdong, 51803, China
Zhengzhou Henan, 45000, China
Wuhan Hubei, 43002, China
Chifeng Inner Mongolia, 02409, China
Nanjing Jiangsu, , China
Nantong Jiangsu, 22600, China
Suzhou Jiangsu, 21500, China
Taiyuan Shanxi, 03000, China
Xian Shanxi, 71006, China
Chengdu Sichuan, 61004, China
Tianjin Tianjin, 30002, China
Hangzhou Zhejiang, 31000, China
Wenzhou Zhejiang, 32500, China
Beijing , 10004, China
Beijing , 10073, China
Lanzhou , , China
Shanghai , 20002, China
Brno Bohunice Czech Republic, 625 0, Czechia
Hradec Kralove CZE, 500 0, Czechia
Ostrava Poruba, 708 5, Czechia
Aarhus , 8000, Denmark
Copenhagen , DK-21, Denmark
Roskilde , 4000, Denmark
Helsinki , FIN 0, Finland
Turku , 20520, Finland
Bordeaux , 33076, France
Lyon Cedex , 69373, France
Nantes Cedex 1 , 44093, France
Paris Cedex 10 , 75475, France
Mannheim Baden-Wuerttemberg, 68305, Germany
Aachen , 52074, Germany
Berlin , 13353, Germany
Frankfurt , 60590, Germany
Jena , 07740, Germany
Luebeck , 23538, Germany
Debrecen , 4032, Hungary
Kaposvar , 7400, Hungary
Kecskemet , 6001, Hungary
Kolkata West Bengal, 70016, India
Delhi , 110 0, India
Petah Tikva , , Israel
Ramat Gan , 52621, Israel
Tel Aviv , 64239, Israel
Bologna BO, 40138, Italy
Milano MI, 20122, Italy
Reggio Emilia RE, 42123, Italy
Roma RM, 00161, Italy
Verona VR, 37126, Italy
Nagoya Aichi, 453-8, Japan
Toyoake city Aichi, 470 1, Japan
Kashiwa Chiba, 277 8, Japan
Fukuoka city Fukuoka, 812-8, Japan
Fukushima city Fukushima, 960 1, Japan
Sapporo city Hokkaido, 060 8, Japan
Kobe-city Hyogo, 650-0, Japan
Kurashiki-city Okayama, 710-8, Japan
Osaka Sayama Osaka, 589 8, Japan
Suita Osaka, 565 0, Japan
Sunto Gun Shizuoka, 411 8, Japan
Shimotsuke Tochigi, 329-0, Japan
Chuo-city Yamanashi, 409-3, Japan
Akita , 010-8, Japan
Osaka , 545-8, Japan
Yamagata , 990 9, Japan
Uijeongbu si Gyeonggi Do, 11759, Korea, Republic of
Seoul Seocho Gu, 06591, Korea, Republic of
Seoul , 03080, Korea, Republic of
Seoul , 03722, Korea, Republic of
Seoul , 06351, Korea, Republic of
Kuantan Pahang, 25100, Malaysia
Subang Jaya Selangor, 47500, Malaysia
Pulau Pinang , 10990, Malaysia
Selangor , 68000, Malaysia
Amsterdam , 1081 , Netherlands
Bergen , 5021, Norway
Oslo , 0372, Norway
Trondheim , 7006, Norway
Lisboa , 1099 , Portugal
Porto , 4200-, Portugal
Vila Nova de Gaia , 4434 , Portugal
Moscow , 12764, Russian Federation
Saint Petersburg , 19102, Russian Federation
Singapore , 11922, Singapore
Singapore , 16960, Singapore
Bratislava Slovak Republic, 83310, Slovakia
Kosice Slovak Republic, 040 6, Slovakia
Granada Andalucia, 18014, Spain
Badalona Catalunya, 08916, Spain
Barcelona Catalunya, 08036, Spain
El Palmar Murcia, 30120, Spain
Pamplona Navarra, 31008, Spain
Madrid , 28046, Spain
Goteborg , 413 4, Sweden
Lund , 221 8, Sweden
Stockholm , 141 8, Sweden
Bellinzona , 6850, Switzerland
Zürich , 8091, Switzerland
Kaohsiung City , 83301, Taiwan
Taichung , 40447, Taiwan
London , W12 0, United Kingdom
Nottingham , NG5, United Kingdom
Oxford , OX3 7, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.